Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; Maurice Wilkins Centre for Molecular Biodiscovery, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand.
Human Nutrition Unit, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; School of Biological Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand; CINTESIS - Centro de Investigação em Tecnologias e Serviços de Saúde | NOVA Medical School, NOVA University of Lisbon, 1169-056 Lisboa, Portugal.
Obes Res Clin Pract. 2021 Jan-Feb;15(1):42-48. doi: 10.1016/j.orcp.2020.12.007. Epub 2021 Jan 9.
Weight reduction is effective in preventing T2D however, weight reduction and maintenance is difficult to achieve on a population scale. Serum insulin-like growth factor II (IGF-II) and IGF-II receptor (IGF2R) have been associated with diabetic status and body weight in prior studies and, in addition, IGF-II has been indicated as predictive of future weight change. We measured these serum markers in participants with obesity/overweight and prediabetes from the New Zealand arm of the PREVIEW lifestyle intervention randomised trial before and after an 8-week low energy diet (LED).
Total IGF-II (n = 223) and soluble IGF2R (n = 151) were measured using commercial ELISA kits on fasted serum samples taken prior to an 8-week LED and also from participants completing the LED.
IGF-II levels were not correlated with baseline body weight although mean levels did significantly decrease following the LED. Change in IGF-II serum level was correlated to fasting glucose change (p = 0.04) but not to weight change. Baseline serum IGF2R was correlated with BMI (p = 0.007) and was significantly higher in Māori compared to European Caucasian participants independent of body weight (p = 0.0016). Following LED, IGF2R change was positively associated with weight change (p = 0.02) when corrected for ethnicity. Pre-LED levels of these serum markers were not predictive of the magnitude of weight loss over the 8 weeks.
Neither marker was useful in predicting magnitude of short-term weight loss. IGF2R is positively associated with BMI and is higher in Māori compared to European Caucasian individuals.
体重减轻对于预防 T2D 是有效的,然而,在人群中实现体重减轻和维持是困难的。在之前的研究中,血清胰岛素样生长因子 II(IGF-II)和 IGF-II 受体(IGF2R)与糖尿病状态和体重有关,此外,IGF-II 已被表明可预测未来的体重变化。我们在新西兰 PREVIEW 生活方式干预随机试验的肥胖/超重和糖尿病前期参与者中测量了这些血清标志物,在 8 周的低能量饮食(LED)之前和之后进行了测量。
使用商业 ELISA 试剂盒在空腹血清样本中测量总 IGF-II(n = 223)和可溶性 IGF2R(n = 151),这些样本在 8 周 LED 之前和完成 LED 的参与者中采集。
IGF-II 水平与基线体重无关,尽管平均水平在 LED 后显著降低。IGF-II 血清水平的变化与空腹血糖变化相关(p = 0.04),但与体重变化无关。基线血清 IGF2R 与 BMI 相关(p = 0.007),且在毛利人参与者中明显高于欧洲白种人参与者,与体重无关(p = 0.0016)。在 LED 后,当校正种族时,IGF2R 变化与体重变化呈正相关(p = 0.02)。这些血清标志物的预 LED 水平不能预测 8 周内体重减轻的幅度。
这两个标志物都不能预测短期体重减轻的幅度。IGF2R 与 BMI 相关,且在毛利人参与者中高于欧洲白种人参与者。